ReviewHeart failure reviews2014
Clinical utility of antigen carbohydrate 125 in heart failure.
Review in Heart failure reviews, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 80 citations in OpenAlex.
- Carbohydrate antigen 125 and clinical outcomes in heart failure: systematic review and meta-analysis.BMC cardiovascular disorders · 2025Pooled it
- Residual congestion and urinary sodium and chloride trajectories in acute heart failure.Internal and emergency medicine · 2026Article
- Evolution of CA 125 and NT-proBNP in stable patients with Fontan circulation: longitudinal analysis with sex perspective.International journal of cardiology. Congenital heart disease · 2026Article
- Subclinical Inflammation in Ischemic Heart Disease and Its Role in the Transition to Heart Failure.Life (Basel, Switzerland) · 2026Review
- Carbohydrate Antigen 125 as a Marker of Decongestion and Early Outcomes in Acute Decompensated Heart Failure: Insights From a Tertiary Hospital in Western Kenya.Cardiology research and practice · 2026Article
- The Expanding Role of Carbohydrate Antigen 125 in Heart Failure: From Tumour Marker to a Cornerstone of Heart Failure Management. An Updated Narrative Review.Cardiac failure review · 2026Review
- Contemporary Perspectives on Congestion in Heart Failure: Bridging Classic Signs with Evolving Diagnostic and Therapeutic Strategies.Diagnostics (Basel, Switzerland) · 2025Review
- Biomarkers of Hemodynamic Congestion in Heart Failure.Current heart failure reports · 2024Review
- Carbohydrate Antigen 125 (CA 125): A Novel Biomarker in Acute Heart Failure.Diagnostics (Basel, Switzerland) · 2024Review
- Tumor biomarkers in evaluating the severity and prognosis of idiopathic pulmonary arterial hypertension: A comprehensive analysis.Clinical and translational science · 2024Article
- Cardiovascular Biomarkers in Cardio-Oncology: Antineoplastic Drug Cardiotoxicity and Beyond.Biomolecules · 2024Review
- Renal Biomarkers in Cardiovascular Patients with Acute Kidney Injury: A Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2023Review
- CA125: a novel cardiac biomarker for infants with congenital diaphragmatic hernia.Pediatric research · 2023Article
- Carbohydrate antigen 125 in congestive heart failure: ready for clinical application?Frontiers in oncology · 2023Review
- Tumor marker response to SARS-CoV-2 infection among patients with cancer.Cancer medicine · 2022Article
- Non-Invasive Assessment of Congestion by Cardiovascular and Pulmonary Ultrasound and Biomarkers in Heart Failure.Diagnostics (Basel, Switzerland) · 2022Review
- CA-125 variation in acute heart failure: a single-centre analysis.ESC heart failure · 2022Article
- Multimodal Strategies for the Diagnosis and Management of Refractory Congestion. An Integrated Cardiorenal Approach.Frontiers in physiology · 2022Review
- Early carbohydrate antigen 125 as a mortality predictor in hospitalized patients with coronavirus disease 2019.Frontiers in cardiovascular medicine · 2022Article
- Lung ultrasound in outpatients with heart failure: the wet-to-dry HF study.ESC heart failure · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, there has been a proliferation of new biomarkers with potential prognostic implication in heart failure (HF). Nevertheless, most of them do not fulfill the required criteria for being used in daily clinical practice. Tumor marker antigen carbohydrate 125 (CA125), a glycoprotein widely used for ovarian cancer monitoring, is synthesized by epithelial serous cells in response to fluid accumulation and/or cytokine stimuli. This glycoprotein has been emerged as a potential biomarker in HF. Plasma CA125 correlates with clinical, hemodynamic, and echocardiographic parameters related to the severity of the disease. High levels have shown to be present in the majority of acutely decompensated patients, and in this setting, it has shown to be independently related to mortality or subsequent admission for acute HF. In addition, certain characteristics such as wide availability and the close correlation between plasma changes with disease severity and clinical outcomes have increased the interest of researchers about the potential of this glycoprotein for monitoring and guiding therapy in HF. In this article, we have reviewed the available evidence supporting the potential role of CA125 as a biomarker in HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.